GLP-1 Companion Products Market (2026 - 2033)

GLP-1 Companion Products Market Summary

The global GLP-1 companion products market size was valued at USD 204.8 billion in 2025 and is projected to grow from USD 225.9 billion in 2026 to USD 479.0 billion by 2033, at a CAGR of 11.3% from 2026 to 2033. North America held the largest market share of 37.8% in 2025. Consumers using GLP-1 medications are increasingly seeking products that help address reduced appetite, support adequate protein intake, maintain hydration, promote digestive health, and preserve lean muscle mass during treatment.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

This trend is encouraging manufacturers to develop specialized product portfolios, including high-protein foods and beverages, hydration solutions, digestive-health products, meal replacements, and nutrient-dense supplements tailored to the unique needs of GLP-1 users. The growing emphasis on personalized nutrition, preventive healthcare, and long-term weight-management support is accelerating market expansion. The increasing integration of digital health platforms, nutrition coaching, and AI-enabled wellness programs is further enhancing consumer engagement and treatment adherence, while ongoing product innovation and the entry of food, nutrition, and wellness companies into the GLP-1 ecosystem continue to create new growth opportunities for the GLP-1 companion product industry.

To learn more about this report, Download Free Sample Report

The market is growing as rising awareness of the nutritional and lifestyle challenges associated with GLP-1 therapy encourages consumers to adopt specialized support products into their daily health routines. Reduced appetite, lower food intake, digestive discomfort, hydration concerns, and the risk of lean muscle loss are prompting consumers to seek protein-enriched foods and beverages, hydration solutions, digestive health products, and micronutrient supplements to support overall well-being during treatment. In addition, the growing emphasis on preventive healthcare, healthy aging, and long-term weight management is accelerating demand for companion products that can help individuals maintain nutritional adequacy and sustain treatment outcomes.

Market Dynamics

Analyst Perspective

The global GLP-1 companion products market is witnessing strong growth as the adoption of GLP-1 therapies for weight management and metabolic health continues to expand. Rising awareness of nutrition support during treatment is increasing demand for products that help maintain muscle mass, support hydration, improve digestive health, and address nutritional deficiencies, in line with preventive healthcare and personalized nutrition trends. Market growth will be supported by clinically validated, targeted nutritional formulations and strategic healthcare partnerships. Companies offering protein, fiber, electrolyte, probiotic, and micronutrient solutions tailored to GLP-1 users, alongside collaborations with healthcare providers, pharmacies, and digital health platforms, are expected to strengthen consumer trust and drive long-term market expansion.

Consumer Insights

GLP-1 companion products are increasingly being perceived as an essential component of the overall weight-management and wellness journey, rather than as standalone nutritional products. As the use of GLP-1 therapies expands globally, consumers are becoming more conscious of the nutritional and lifestyle adjustments required during treatment, including maintaining adequate protein intake, supporting hydration, managing digestive comfort, and preserving overall nutritional balance. This shift in consumer behavior has contributed to growing demand for companion products across major markets such as the U.S., Canada, Germany, the UK, Australia, and other developed healthcare economies. To address these evolving needs, manufacturers are increasingly introducing specialized product portfolios tailored to GLP-1 users.

To learn more about this report, Download Free Sample Report

Personalization and outcome-oriented nutrition have emerged as key purchasing considerations among GLP-1 users. Rather than seeking general wellness products, consumers increasingly prefer solutions that address specific treatment-related needs and can be incorporated into structured weight-management routines. The growing use of digital health platforms, telehealth services, and nutrition-coaching programs has further strengthened consumer awareness regarding the importance of balanced nutrition throughout treatment. As a result, demand is increasing for convenient, nutrient-dense products such as ready-to-drink protein beverages, meal replacements, functional snacks, electrolyte formulations, probiotics, and micronutrient supplements. Consumers are also demonstrating a preference for products that provide transparent nutritional information, clinically supported ingredients, and clear functional benefits that align with their weight-management objectives.

Product Insights

The hydration & recovery product market segment accounted for a revenue share of 26.2% in 2025, driven by the prevalence of dehydration, electrolyte imbalance, fatigue, reduced food intake, and gastrointestinal side effects among GLP-1 users. As appetite suppression often leads to reduced food and fluid intake, consumers increasingly seek hydration solutions, electrolyte supplements, recovery beverages, and nutrient-dense formulations to help maintain energy levels and support overall wellness during treatment. Unlike specialized metabolic support products that target a specific subset of users, hydration products appeal to a broader consumer base throughout the entire treatment journey, from initiation through long-term maintenance. Consequently, manufacturers are increasingly introducing hydration-focused formulations enriched with electrolytes, protein, vitamins, and minerals to address the nutritional challenges associated with GLP-1 therapy. In January 2026, Maeva launched a dedicated metabolic wellness platform featuring hydration support products specifically formulated for GLP-1 users, alongside personalized nutrition solutions designed to support strength and recovery during weight-loss treatment.

To learn more about this report, Download Free Sample Report

The appetite & metabolic support products market segment is expected to grow at a CAGR of 12.5% from 2026 to 2033, as consumers increasingly seek solutions that complement the physiological effects of GLP-1 therapies and support long-term metabolic health. While GLP-1 medications effectively suppress appetite, many users require additional nutritional support to manage reduced food intake, maintain nutrient adequacy, preserve lean muscle mass, and sustain metabolic function. This has led to growing demand for protein-enriched products, fiber supplements, metabolic wellness formulations, nutrient-dense meal replacements, and specialized dietary solutions designed specifically for individuals undergoing GLP-1 treatment. As consumers become more focused on maintaining results beyond active weight loss, appetite and metabolic support products are gaining traction as an essential component of comprehensive obesity management.

For instance, in May 2025, Oikos expanded beyond yogurt and introduced protein shakes specifically developed for users of GLP-1 medications, addressing increasing demand for protein-rich metabolic support products.

Distribution Channel Insights

The sales of GLP-1 companion products through online channels accounted for a revenue share of 23.6% in 2025, owing to their ability to provide convenient access to specialized nutrition products, hydration solutions, supplements, meal replacements, and wellness programs tailored for GLP-1 users. Consumers undergoing GLP-1 therapy frequently seek personalized products and educational resources that may not be readily available through traditional retail channels, making online platforms a preferred purchasing destination. Additionally, subscription-based purchasing models, direct access to product information, recurring delivery services, telehealth integration, and personalized product recommendations have further strengthened consumer reliance on e-commerce platforms. The channel also enables brands to directly engage with consumers, gather health and behavioral insights, and rapidly introduce new GLP-1-focused offerings in response to evolving market needs.

To learn more about this report, Download Free Sample Report

The sales of GLP-1 companion products through the D2C channel are expected to grow at a CAGR of 13.1% from 2026 to 2033 as brands increasingly seek to establish direct relationships with consumers and deliver personalized support throughout their treatment journey. D2C platforms enable companies to combine product sales with digital coaching, symptom tracking, nutritional guidance, subscription services, and telehealth support, creating comprehensive wellness ecosystems tailored to the specific needs of GLP-1 users. Consumers are increasingly favoring D2C models due to the convenience of home delivery, personalized product recommendations, flexible subscription options, and access to educational content that supports long-term weight management. Moreover, D2C strategies enable companies to collect real-time consumer feedback and rapidly refine product offerings in response to evolving patient needs and treatment experiences.

Regional Insights

The GLP-1 companion products market in North America accounted for a revenue share of 37.8% in 2025, driven by the rapid commercialization of specialized nutrition solutions designed to address the evolving needs of individuals using GLP-1 therapies. Consumers are increasingly seeking products that help maintain adequate protein intake, hydration levels, digestive health, and overall nutritional balance while undergoing weight-management treatment. Another important factor supporting market growth is the increasing integration of companion products into broader health and wellness ecosystems. Companies are expanding beyond standalone nutritional offerings and introducing personalized programs that combine dietary guidance, product recommendations, education, and ongoing support. This approach is helping consumers better manage treatment-related lifestyle changes while creating opportunities for recurring engagement and product adoption.

To learn more about this report, Download Free Sample Report

In March 2025, The Vitamin Shoppe launched its GLP-1 Support supplement line under the Whole Health Rx platform. The portfolio includes protein, fiber, probiotic, multivitamin, and comprehensive nutritional-support formulations designed to help address nutrient gaps and digestive-health needs among individuals using GLP-1 medications.

U.S. GLP-1 Companion Products Market Trends

The U.S. GLP-1 companion product industry accounted for the largest share, at 85.9%, in 2025, due to its large GLP-1 user base, advanced digital health ecosystem, and growing consumer demand for personalized obesity management support. One of the most significant trends in the country is the increasing convergence of telehealth, digital coaching, and medication management into integrated consumer-facing platforms. Consumers are no longer seeking access to medication alone but increasingly demand continuous support, including meal planning, side-effect management, fitness guidance, and long-term habit formation. This trend is further supported by growing efforts to expand access to obesity treatment.

For instance, in 2026, the Centers for Medicare & Medicaid Services (CMS) launched the Medicare GLP-1 Bridge demonstration program to improve access to GLP-1 therapies for eligible beneficiaries, a move expected to increase the addressable consumer base for companion solutions. Additionally, Walmart expanded its digital health offerings in 2026 to include weight-management and GLP-1 support services through its virtual care ecosystem, reflecting the growing emphasis on comprehensive patient support.

Europe GLP-1 Companion Products Market Trends

The GLP-1 companion product industry in Europe accounted for a share of 22.1% in 2025, driven by the increasing emphasis on clinical nutrition and structured lifestyle support as part of long-term weight management programs. Consumers and healthcare professionals across the region are placing greater focus on ensuring adequate nutrient intake, maintaining physical function, and supporting healthy aging during GLP-1 treatment. This is encouraging demand for companion products that provide protein enrichment, micronutrient support, digestive wellness benefits, and portion-controlled nutrition.

In January 2026, Marks & Spencer launched a dedicated range of nutrient-dense food products designed for consumers using GLP-1 weight-loss medications. The portfolio includes high-protein meals, yogurt bowls, wraps, and snacks formulated to help individuals maintain adequate nutrient intake despite reduced appetite. The launch reflects the growing involvement of mainstream food retailers in meeting the evolving dietary requirements of GLP-1 users.

The Germany GLP-1 companion products market commands a significant share of Europe due to its strong healthcare infrastructure, increasing obesity prevalence, and high adoption of digital health solutions. Consumers typically exercise heightened scrutiny of health-related products and often prioritize evidence-based formulations over trend-driven wellness products. As a result, companion products that provide clear nutritional functionality, ingredient transparency, and clinically supported benefits are gaining traction among GLP-1 users. Germany’s aging population is contributing to demand for companion products that support healthy body composition, physical function, and nutritional adequacy during weight-management interventions. The market is further supported by rising consumer willingness to spend on premium health products that offer convenience, quality assurance, and measurable health outcomes.

Asia Pacific GLP-1 Companion Products Market Trends

The GLP-1 companion product industry in Asia Pacific is projected to grow at a CAGR of 12.7% from 2026 to 2033, driven by the increasing consumer focus on metabolic wellness, preventive nutrition, and personalized health management. Consumers across the region are becoming more proactive in managing their nutritional intake during GLP-1 therapy, driving demand for protein-enriched foods, hydration products, digestive health solutions, and nutrient-dense meal alternatives.

In March 2026, Japanese health-tech company MedIshin launched "Mend," a nationwide medical weight-management platform that combines GLP-1 prescriptions, registered dietitian support, blood testing, and personalized health monitoring. The launch highlights the growing demand in Asia Pacific for integrated care models that combine medication with nutrition and lifestyle support, creating favorable conditions for GLP-1 companion products and personalized nutrition solutions.

The China GLP-1 companion products market is the fastest-growing in Asia Pacific, driven by a rapidly expanding obesity population, growing awareness of weight-related health risks, and strong domestic innovation in the metabolic health sector. One of the most important trends in the country is the emergence of locally developed obesity therapies and integrated weight-management ecosystems designed specifically for consumers. As the number of consumers receiving GLP-1 therapies increases, there is a growing demand for products that help optimize nutritional intake despite reduced appetite and lower food consumption. The approval of Innovent's mazdutide in 2025, the world's first GLP-1/glucagon dual agonist approved for chronic weight management, has significantly increased interest among consumers and healthcare providers in obesity treatment and related support services. Additionally, companies are increasingly leveraging digital platforms and e-commerce channels to distribute weight-management products and engage consumers throughout their treatment journey. China has also witnessed continued investment in next-generation obesity therapies, including the advancement of Novo Nordisk and United Biotechnology's UBT251 program, highlighting the country's growing importance in the global metabolic health landscape.

Central & South America GLP-1 Companion Products Market Trends

The GLP-1 companion product industry in Central & South America is projected to grow at 11.6% CAGR from 2026 to 2033, as consumers increasingly seek affordable nutritional support solutions that complement long-term weight management and metabolic health. One of the primary factors driving market growth is the gradual expansion of access to GLP-1 therapies across major countries such as Brazil, which is increasing awareness of the nutritional requirements associated with these treatments. Trend across the region is the rising use of private obesity clinics, endocrinology centers, and wellness programs that combine pharmacological treatment with nutritional counseling and lifestyle interventions. This is creating demand for companion products that help consumers maintain nutritional adequacy, support digestive health, and manage dietary changes associated with reduced appetite. As more consumers adopt GLP-1 medications, demand is rising for protein-rich foods, hydration products, digestive-health solutions, and nutrient-dense meal options that help address reduced appetite and support overall nutritional balance.

Middle East & Africa GLP-1 Companion Products Market Trends

The Middle East & Africa GLP-1 companion product industry is projected to grow at a CAGR of 12.2% from 2026 to 2033, driven by arising emphasis on preventive healthcare and chronic disease management, particularly among populations actively seeking solutions to improve metabolic health and overall well-being. The increasing focus on structured patient-support programs, with healthcare stakeholders emphasizing the importance of combining medication with nutrition planning, physical activity, and behavioral guidance. This creates favorable conditions for companion products designed to support treatment adherence, nutritional adequacy, and long-term lifestyle management. In addition, expanding pharmaceutical investment and improving the availability of GLP-1 therapies across several Middle Eastern and African markets are increasing awareness of the complementary role of nutrition and wellness products throughout the treatment journey. As consumers become more engaged in proactive health management, demand for specialized companion products is expected to strengthen across the region.

Eurasia GLP-1 Companion Product Market Trends

The GLP-1 companion product industry in Eurasia is projected to grow at a CAGR of 11.2% from 2026 to 2033 as the region experiences a rapid expansion in access to GLP-1 therapies, particularly through domestic manufacturing, local pharmaceutical innovation, and increasing availability of lower-cost alternatives. A major factor driving demand for companion products is the growing need for nutritional optimization and treatment-support solutions among first-time GLP-1 users, many of whom are seeking guidance on protein intake, hydration, digestive wellness, and sustainable dietary habits during treatment. The emergence of oral GLP-1 formulations and broader treatment accessibility is encouraging consumers to seek convenient, everyday nutritional solutions that can be integrated into long-term health-management routines. As awareness of treatment-support requirements increases, demand for protein-enriched foods, meal-support products, hydration solutions, and digestive-health formulations is expected to strengthen across Eurasian markets.

In November 2025, Promomed received regulatory approval for Semaltara, Russia's first domestically produced oral semaglutide product. The launch expanded access to GLP-1 therapy through a non-injectable format and reflects the region's growing focus on improving treatment accessibility. Increased adoption of oral therapies is expected to support demand for convenient companion nutrition products that can be integrated into daily routines.

Key GLP-1 Companion Products Company Insights

The GLP-1 companion products market is characterized by the growing presence of nutrition, wellness, functional food, dietary supplement, and digital health solution providers focused on supporting individuals throughout their GLP-1 treatment journey. Market participants are increasingly developing specialized product portfolios that address evolving consumer needs for nutritional adequacy, hydration, digestive wellness, metabolic health, and long-term weight management. Continuous innovation in high-protein foods, nutrient-dense meal solutions, functional beverages, vitamins, probiotics, and personalized wellness offerings is contributing to category expansion and product differentiation. In addition, companies are strengthening their market presence through omnichannel distribution strategies, including e-commerce platforms, direct-to-consumer channels, pharmacies, health and wellness retailers, and subscription-based service models, enabling broader consumer access to companion solutions.

To learn more about this report, Download Free Sample Report

Key GLP-1 Companion Products Companies

The following key companies have been profiled for this study of the GLP-1 companion products market.

• Nature Made

• Nestle S.A.

• Herba Life Ltd.

• The Vitamin Shoppe

• Conagra Brands Inc.

• Danone S.A.

• Abbott

• Amway Corp

• GNC

• Smoothie King

Recent Developments

• In January 2026, Maeva launched a science-backed nutrition system for GLP-1 users featuring targeted metabolic boosters, personalized nutrition shakes, and wellness products designed to support metabolic health during weight-loss treatment.

• In January 2026, Bodie*z expanded into the UK market with protein hydration powders targeting GLP-1 users, combining high-protein content with hydration benefits to support muscle preservation and recovery.

• In August 2025, Eden partnered with Gainful to introduce personalized hydration bundles and nutritional support programs tailored to individuals undergoing GLP-1 treatment, reflecting the increasing integration of hydration products within broader companion ecosystems.

• In May 2025, Oikos expanded beyond yogurt and introduced protein shakes specifically developed for users of GLP-1 medications, addressing increasing demand for protein-rich metabolic support products.

Global GLP-1 Companion Products Market Report Segmentation

This report forecasts revenue growth at the global, regional & country level and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global GLP-1 companion product market report based on product, distribution channel, and region:

To learn more about this report, Download Free Sample Report

• Product Outlook (Revenue, USD Billion, 2021 - 2033)

  • Muscle Preservation Powders

    • Protein Powders

    •  RTD Protein Beverages

    •  Protein Bars

    •  Others

  • Digestive Health Products

    • Fiber Supplements

    • Probiotics Supplements

    • Digestive Enzyme Supplements

    • Others

  • Nutrient Density Support

    • Multivitamin Supplements

    • Meal Replacement Products

    • Others

  • Appetite & Metabolic Support

    • Satiety Support Products

    • Appetite Management Supplements

    • Others

  • Hydration & Recovery Products

    • Electrolyte Beverages

    • Recovery Hydration Products

    • Functional Hydration Mixes

    • Others

  • Others

• Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)

  • Hypermarkets & Supermarkets

  • Pharmacies & Drug Stores

  • Specialty Stores

  • D2C

  • Online (E-commerce)

  • MLM (Direct Sales)

  • Others

• Regional Outlook (Revenue, USD Billion, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

  • Asia Pacific

    • China

    • Japan

    • India

    • Australia & New Zealand

    • South Korea

    • Indonesia

    • Malaysia

    • Vietnam

    • Taiwan

  • Central & South America

    • Brazil

    • Colombia

    • Ecuador

    • El Salvador

    • Peru

    • Honduras

  • Middle East & Africa

    • Saudi Arabia

    • Turkey

  • Eurasia

    • Mongolia

    • Kazakhstan

    • Uzbekistan

Research Methodology

The GLP-1 companion product market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each GLP-1 companion product segment quantified using the revenue-capture definitions in the table below.

Delivered Customizations

This report has been delivered with the following In-depth customizations